Ligelizumab improves sleep interference in chronic spontaneous urticaria patients Medical Dialogues Editorial Team22 March 2022 9:00 AM ISTGermany: Ligelizumab demonstrated effective and persistent responses in managing sleep interference in chronic spontaneous urticaria (CSU) patients,...
Setback: Sanofi to halt Dupixent Phase 3 trial MD Bureau21 Feb 2022 4:50 PM ISTParis: Sanofi has recently announced that the Phase 3 trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous...
Ligelizumab fails to show superiority to omalizumab in chronic spontaneous urticaria: Clinical trials Hina Zahid25 Dec 2021 9:00 AM ISTLigelizumab, an investigational treatment for chronic spontaneous urticaria (CSU), failed to show superiority to omalizumab in two identical phase 3...
Ligelizumab and omalizumab effective for treating chronic spontaneous urticaria: JAMA MD Editorial Team28 Sept 2021 6:45 PM ISTThailand: Biologic agents ligelizumab, 72 or 240 mg, and omalizumab, 300 or 600 mg can be recommended as effective treatments for chronic spontaneous...
Dupilumab significantly improves itch and hives in chronic spontaneous urticaria patients: Study Hina Zahid5 Aug 2021 9:00 AM ISTUSA: Adding Dupixent (dupilumab) to standard-of-care antihistamines significantly reduced itch and hives in patients with moderate-to-severe chronic...
Ligelizumab more effective than Omalizumab in chronic spontaneous urticaria: Study Medha Baranwal6 May 2021 6:00 PM ISTUSA: Ligelizumab is more effective in reducing chronic spontaneous urticaria (CSU) severity compared with omalizumab, according to findings from a...
High dose Levocetrizine may benefit Chronic spontaneous Urticaria patients Dr.Niharika Harsha B9 July 2020 4:19 PM ISTResearchers have found that High-dose levocetirizine was shown to be effective in the treatment of chronic spontaneous urticaria (CSU). CSU is a type...
